On Monday, anti epidemic stocks in Hong Kong stocks continued to strengthen, with Geli pharmaceutical-b (01672. HK) and Kaifa Pharmaceutical (09939. HK) leading the gains, rising 18.66% and 14.09% respectively.
In fact, the concept of anti epidemic has led to a sharp rise in a number of pharmaceutical companies in the short term. Taking Geli pharmaceutical as an example, the company has increased by more than 40% in nearly 15 trading days. At the same time, the company announced last weekend that it had submitted an application for listing license of ritonavir (100 mg film coated tablets) to Hong Kong Special Administrative Region of China.
It is reported that ritonavir tablets, a product of gelly pharmaceutical, was approved by the State Drug Administration of China in September 2021 (drug approval number: Guoyao Zhunzi h20213698). It is the only ritonavir tablets that have passed bioequivalence research and been approved for marketing in China. In addition, Pfizer's paxlovid is packaged in a combination of two 150mg nimatovir tablets and one 100mg ritonavir tablet.
At present, it has applied for listing in 12 international markets (Europe, Germany, Portugal, France, Italy, Italy, Italy, Italy, Italy, Germany and Italy).
In addition, the national health and Health Committee released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth), and wrote two specific anti COVID-19 virus drugs PF-07321332/ Ritonavir Tablets (Paxlovid) approved by the State Administration of drug administration and domestic monoclonal antibody (Alba monoclonal antibody / romicwell monoclonal antibody injection) to the diagnosis and treatment plan.
In addition to Geli pharmaceutical, which has risen sharply, Shijiazhuang Pharmaceutical Group (01093. HK) and Cansino Biologics Inc(688185) (06185. HK) have successively announced that their covid-19 vaccine has been approved by the State Food and Drug Administration for clinical trials. This approved measure triggered an upsurge of market funds on the concept of anti epidemic.
Relevant analysis points out that at present, a number of high-quality companies in the pharmaceutical sector have entered a reasonable or even exceeded the valuation range, and in the past year, the pharmaceutical sector, especially the Hong Kong stock pharmaceutical sector, has undergone significant adjustment. It is expected that covid-19 and other related concepts will continue to drive the recovery of the pharmaceutical sector.
